# TNG462

Source: https://onco.cc/drugs/tng462/  
OnCo record `tng462` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

TNG462 is an experimental small-molecule drug from Tango Therapeutics in phase 2 trials for pancreatic ductal adenocarcinoma and non-small-cell lung cancer, aimed at PRMT5 (MTAP-deleted cancers).

## Summary

TNG462 is a small-molecule drug developed by Tango Therapeutics and Servier Bio-Innovation. Its target is PRMT5 (MTAP-deleted cancers) (the sponsor names PRMT5). The sponsor states: A selective PRMT5 inhibitor administered orally, developed for tumours with an MTAP homozygous deletion. ClinicalTrials.gov describes the intervention as: TNG462, a selective PRMT5 inhibitor, will be administered orally. It is the investigational product in 3 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, in pancreatic ductal adenocarcinoma and non-small-cell lung cancer. The largest, NCT05732831, plans to enrol 225 participants with primary completion expected 2027-06. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: small molecule
- Mechanism: A selective PRMT5 inhibitor administered orally, developed for tumours with an MTAP homozygous deletion.

## Sources

- ClinicalTrials.gov: trials of TNG462: https://clinicaltrials.gov/search?intr=TNG462

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- targets: [PRMT5 (MTAP-deleted cancers)](https://onco.cc/targets/prmt5-mtap/)
- companies: [Servier](https://onco.cc/companies/servier/), [Tango Therapeutics](https://onco.cc/companies/tango-therapeutics/)
- trials: [S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP](https://onco.cc/trials/nct06188702/), [Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors](https://onco.cc/trials/nct05732831/), [Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients](https://onco.cc/trials/nct06922591/)

---
JSON: https://onco.cc/api/v1/entities/tng462.json